We are live on ! Find out more
CRNX icon

Crinetics Pharmaceuticals
CRNX

80 hedge funds and large institutions have $465M invested in Crinetics Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 27 increasing their positions, 26 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

8% more capital invested

Capital invested by funds: $429M → $465M (+$36.1M)

4% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 26

0.92% more ownership

Funds ownership: 92.42% → 93.35% (+0.92%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

6% less funds holding

Funds holding: 85 → 80 (-5)

45% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 11

Holders
80
Holders Change
-5
Holders Change %
-5.88%
% of All Funds
1.4%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
6
Increased
27
Reduced
26
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
DCM
Driehaus Capital Management
Illinois
+$8.52M
2
SFM
Sphera Funds Management
Israel
+$4.41M
3
OM
Opaleye Management
Massachusetts
+$2.91M
4
Deutsche Bank
Deutsche Bank
Germany
+$1,000K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$867K

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$7.96M
2
EAM
Eventide Asset Management
Massachusetts
-$2.46M
3
VC
Vivo Capital
California
-$1.89M
4
Citadel Advisors
Citadel Advisors
Florida
-$661K
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$497K
Name Holding Trade Value Shares
Change 		Change in
Stake
US Bancorp
76
US Bancorp
Minnesota
$2K +$790 +51 +81%
Daiwa Securities Group
77
Daiwa Securities Group
Japan
$1K – – –
AIG
78
American International Group
New York
$241 +$635 +41 +0.3%
RCM
79
RA Capital Management
Massachusetts
– -$7.96M -564,102 Closed
Citadel Advisors
80
Citadel Advisors
Florida
– -$661K -46,864 Closed
Renaissance Technologies
81
Renaissance Technologies
New York
– -$360K -25,500 Closed
HSBC Holdings
82
HSBC Holdings
United Kingdom
– -$252K -17,868 Closed
Squarepoint
83
Squarepoint
New York
– -$217K -15,406 Closed
Millennium Management
84
Millennium Management
New York
– -$205K -14,538 Closed
Walleye Capital
85
Walleye Capital
New York
– -$171 -12,100 Closed
OQS
86
Occudo Quantitative Strategies
Florida
– -$158K -11,230 Closed
WC
87
Wexford Capital
Florida
– -$43K -3,080 Closed
Canada Life
88
Canada Life
Manitoba, Canada
– -$32K -2,292 Closed
CSS
89
Cubist Systematic Strategies
Connecticut
– -$17.8K -1,151 -99%
CAPTRUST Financial Advisors
90
CAPTRUST Financial Advisors
North Carolina
– +$356 +23 New
1 2 3
4

CRNX Hedge Fund Activity: Q1 2021 in Review

80 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Crinetics Pharmaceuticals (CRNX) for Q1 2021, worth a combined $465M — up 8.4% from $429M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of CRNX and 6 opened new positions — a net loss of 5 holders — while 26 trimmed existing stakes and 27 added.

The largest buyer was Driehaus Capital Management, adding an estimated $8.52M. The largest seller was RA Capital Management, exiting entirely with an estimated $7.96M sold.

  • 80 institutional investors held Crinetics Pharmaceuticals (CRNX) as of Q1 2021, down from 85 in Q4 2020.
  • Funds reported $465M of Crinetics Pharmaceuticals stock for Q1 2021, up 8.4% quarter-over-quarter.
  • 6 funds opened new Crinetics Pharmaceuticals positions in Q1 2021 and 11 closed out, a net change of -5 holders.
  • The largest Crinetics Pharmaceuticals buyer in Q1 2021 was Driehaus Capital Management, an estimated $8.52M added.
  • The largest Crinetics Pharmaceuticals seller in Q1 2021 was RA Capital Management, an estimated $7.96M sold.

Based on aggregated 13F filings for Q1 2021.